• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home The Classics General Medicine Classics

Zidovudine reduces maternal-infant HIV transmission [Classics Series]

byLeah Hawkins Bressler, MD, MPH
November 14, 2015
in General Medicine Classics, Obstetrics and Gynecology Classics, The Classics
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Among pregnant women with HIV, antepartum, intrapartum and neonatal zidovudine therapy reduced maternal-fetal transmission of HIV by two-thirds.

Original Date of Publication: November 1994

Study Rundown: The primary means of human immunodeficiency virus (HIV) infection in young children is maternal-infant transmission. In the 1990s, a staggering 15-45% of infants delivered to women with HIV were expected to be infected, mostly during the process of labor and delivery. Despite medicine’s best treatments, pediatric HIV infection remained a fatal disease, underscoring the importance of preventing transmission. Prior research demonstrated that zidovudine (AZT) reduced maternal transmission of HIV in animal models and promising Phase I studies in pregnant women suggested that zidovudine was safe for use. In the present work, researchers hypothesized that zidovudine administered in the antepartum, intrapartum and neonatal periods would reduce maternal-infant transmission of HIV. After the first interim analysis demonstrated clear benefit to zidovudine therapy for reduction of maternal-infant HIV transmission, the Data Safety Monitoring Board altered study protocol to offer zidovudine to all women. Findings of the present work summarize results of the trial through this first interim analysis.

This landmark study demonstrated that treatment of HIV-positive pregnant women with mild disease (CD4 counts >200) with zidovudine (AZT) achieved a two-thirds reduction in the maternal-fetal transmission of HIV. Findings from the landmark, AIDS Clinical Trials Group 076 (ACTG 076) trial affected a meaningful risk reduction in maternal-infant HIV transmission. Subsequently, in resource-rich settings, the risk of maternal-infant HIV transmission dropped from 20-45% (no treatment) to <1% (antepartum, intrapartum and neonatal antiretroviral therapy and abstinence from breastfeeding and cesarean delivery at 37 weeks for maternal HIV viral load >1000). Strengths included multicenter, international trial with parsimonious randomized, controlled and double-blinded design and outcome ascertainment at multiple times. Limitations include lack of confirmation of HIV diagnosis with polymerase chain reaction and enrollment of women only after the first trimester of pregnancy due to teratogenicity concerns. Further, results do not apply to women with advanced or drug-resistant disease.

Click to read the study in NEJM

Dr. Alan Peaceman, MD, talks to 2 Minute Medicine: Northwestern University School of Medicine; Chief, Division of Obstetrics and Gynecology-Maternal Fetal Medicine.

“This study demonstrated that a regimen of zidovudine incorporating antepartum, intrapartum and neonatal administration reduces rates of maternal-fetal HIV transmission by more than two-thirds. Findings support the universal administration of antiretroviral therapy in the antepartum period, zidovudine intravenously in labor and zidovudine syrup for neonates of pregnant women with HIV.”

In-Depth [randomized controlled trial]: A total of 363 HIV-positive pregnant women with CD4 counts >200 not previously on antiretroviral therapy were randomized to receive zidovudine (n=180) or placebo (n=183) in this multicenter, international (U.S. and France) clinical trial by the AIDS Clinical Trials Group (ACTG 076). Women randomized to zidovudine received antepartum zidovudine orally 5 times daily, intrapartum intravenous zidovudine and zidovudine for the newborn for the first 6 weeks of life. Primary outcome was the incidence of HIV infection among newborns at 18 months of age as detected by enzyme immunoassay, Western blot and serial HIV cultures.

RELATED REPORTS

The 2 Minute Medicine Podcast Episode 6

The Scan by 2 Minute Medicine®: The Genetics of Alzheimer’s Disease, the Silent Killer, a Holiday Blizzard and an HIV Vaccine on the Horizon

Risk scores perform moderately well in discriminating people living with HIV with higher vs lower cardiovascular disease risk

Pregnant, HIV-positive women randomized to receive zidovudine in the antepartum, intrapartum and neonatal periods experienced a 67.5% risk reduction in maternal-fetal HIV transmission (95% CI: 0.41-0.82, P=0.00006). The proportion of HIV-infected infants among women in the ziodovudine treatment group was 8% compared to 26% among women in the placebo group.

Image: PD

©2015 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: HIVzidovudine
Previous Post

Non-toxigenic spores may prevent recurrent Clostridium difficile infection

Next Post

Incidence of non-melanoma skin cancer continues to increase in the USA

RelatedReports

2MM Podcast

The 2 Minute Medicine Podcast Episode 6

February 9, 2023
The Scan by 2 Minute Medicine®:  Ultra-Trail du Mont-Blanc, Taylor Swift, NBA rookie Chet Holmgren and Magic Mushrooms!
The Scan by 2 Minute Medicine®

The Scan by 2 Minute Medicine®: The Genetics of Alzheimer’s Disease, the Silent Killer, a Holiday Blizzard and an HIV Vaccine on the Horizon

March 14, 2023
Few high school students, young adults get HIV testing
Cardiology

Risk scores perform moderately well in discriminating people living with HIV with higher vs lower cardiovascular disease risk

January 3, 2023
Positive physician experience in the Pediatric AIDS Corps
Cardiology

Risk of cardiovascular pathology determined using advanced cardiovascular imaging limited by heterogeneity amongst patients with human immunodeficiency virus

September 17, 2022
Next Post
Increased risk of non-melanoma skin cancer with subsequent keratinocytes carcinoma

Incidence of non-melanoma skin cancer continues to increase in the USA

Radiofrequency catheter ablation effective as first-line therapy for atrial fibrillation [RAAFT-2 trial]

No difference between three methods of catheter ablation for persistent atrial fibrillation [STAR AF II]

Exercise improves aromatase inhibitor-induced arthralgia in breast cancer survivors

Exercise associated with improved quality of life during chemotherapy

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Active surveillance strategies to improve rates of inferior vena cava filter retrieval
  • Intranasal vaccine against Bordetella pertussis invokes seronegative IgA response
  • Hydrochlorothiazide does not impact risk of kidney-stone recurrence
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options